Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Assembly Biosciences (ASMB)
NASDAQ:ASMB
RESEARCH TOOLSreports
Assembly Biosciences (ASMB) Stock Price & Analysis
509 Followers
ASMB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.69 - $20.04
Previous Close$14.93
Volume7.45K
Average Volume (3M)30.37K
Market Cap
$81.86M
Enterprise Value$36.57M
Total Cash (Recent Filing)$46.21M
Total Debt (Recent Filing)$919.00K
Price to Earnings (P/E)-1.1
Beta0.82
Next Earnings
May 09, 2024EPS Estimate
-$3.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.63
Shares Outstanding5,482,752
10 Day Avg. Volume22,959
30 Day Avg. Volume30,366
Standard Deviation0.19
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.93
Price to Sales (P/S)535.02
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue239.00
Enterprise Value/Gross Profit239.00
Enterprise Value/Ebitda-0.50
Forecast
1Y Price Target
$36.00Price Target Upside147.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Assembly Biosciences News
PremiumCompany Announcements
Assembly Biosciences Welcomes New Board Member, Launches Bonus Plan
PremiumCompany Announcements
Assembly Biosciences Executes Reverse Stock Split
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ASMB FAQ
What was Assembly Biosciences’s price range in the past 12 months?
Assembly Biosciences lowest stock price was $7.69 and its highest was $20.04 in the past 12 months.
What is Assembly Biosciences’s market cap?
Currently, no data Available
When is Assembly Biosciences’s upcoming earnings report date?
Assembly Biosciences’s upcoming earnings report date is May 09, 2024 which is in 20 days.
How were Assembly Biosciences’s earnings last quarter?
Assembly Biosciences released its earnings results on Mar 28, 2024. The company reported -$1.86 earnings per share for the quarter, beating the consensus estimate of -$2.82 by $0.96.
Is Assembly Biosciences overvalued?
According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued.
Does Assembly Biosciences pay dividends?
Assembly Biosciences does not currently pay dividends.
What is Assembly Biosciences’s EPS estimate?
Assembly Biosciences’s EPS estimate is -$3.23.
How many shares outstanding does Assembly Biosciences have?
Assembly Biosciences has 5,482,752 shares outstanding.
What happened to Assembly Biosciences’s price movement after its last earnings report?
Assembly Biosciences reported an EPS of -$1.86 in its last earnings report, beating expectations of -$2.82. Following the earnings report the stock price went down -3.008%.
Which hedge fund is a major shareholder of Assembly Biosciences?
Among the largest hedge funds holding Assembly Biosciences’s share is Platinum Investment Management. It holds Assembly Biosciences’s shares valued at N/A.
---
Assembly Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.00 (147.93% Upside)
$36.00 (147.93% Upside)
Hedge Fund Trend
Decreased
By 74.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $480.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.3%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.67%
12-Months-Change
Fundamentals
Return on Equity
-98.95%
Trailing 12-Months
Asset Growth
33.98%
Trailing 12-Months
Company Description
Assembly Biosciences
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.
---
ASMB Stock 12 Months Forecast
Average Price Target
$36.00
▲(147.93% Upside)
Technical Analysis
Best Analysts Covering ASMB
1 Year
1 Year Success Rate
4/27 ratings generated profit
1 Year Average Return
-40.77%
reiterated a buy rating 22 days ago
Copying Salim Syed's trades and holding each position for 1 Year would result in 14.81% of your transactions generating a profit, with an average return of -40.77% per trade.
---